US drug major Eli Lilly has signed a definitive merger agreement for the acquisition of San Diego, California-based biotechnology company SGX Pharmaceuticals in an all-cash transaction.
Under the terms of the deal, Lilly will acquire all of the outstanding shares of SGX common stock for $3.00 per share, for a total price of $64.0 million. Lilly will gain access to SGX' structure-guided drug discovery platform. The US drug major will also benefit from FAST, SGX' fragment-based, protein structure drug discovery technology, as well as a portfolio of preclinical oncology compounds focused on a number of high-value kinase targets.
Since entering into an initial collaboration in 2003, Lilly has partnered with SGX to determine three-dimensional structures of key Lilly drug targets utilizing SGX' proprietary X-ray crystallography technology. The ongoing collaboration also provides Lilly with access to the SGX synchrotron beamline facility, SGX-CAT.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze